| Human immunodeficiency virus I infection
Complera vs Fuzeon
Side-by-side clinical, coverage, and cost comparison for human immunodeficiency virus i infection.Deep comparison between: Complera vs Fuzeon with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsFuzeon has a higher rate of injection site reactions vs Complera based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Fuzeon but not Complera, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Complera
Fuzeon
At A Glance
Oral
Once daily
NRTI/NNRTI fixed-dose combination
SC injection
Twice daily
HIV-1 fusion inhibitor
Indications
- Human immunodeficiency virus I infection
- Human immunodeficiency virus I infection
Dosing
Human immunodeficiency virus I infection One tablet orally once daily with food for adults and pediatric patients weighing at least 35 kg; not recommended in patients with estimated creatinine clearance below 50 mL/min.
Pregnancy One tablet once daily may be continued in virologically suppressed patients (HIV-1 RNA less than 50 copies/mL); monitor viral load closely due to lower rilpivirine exposures during pregnancy.
Rifabutin coadministration Add one additional 25 mg rilpivirine (Edurant) tablet once daily with a meal for the duration of rifabutin coadministration.
Human immunodeficiency virus I infection (Adults) 90 mg (1 mL) SC twice daily injected into the upper arm, anterior thigh, or abdomen.
Human immunodeficiency virus I infection (Pediatric, >=11 kg) 2 mg/kg SC twice daily up to a maximum of 90 mg twice daily injected into the upper arm, anterior thigh, or abdomen; adjust dose with weight changes.
Contraindications
- Coadministration with carbamazepine, oxcarbazepine, phenobarbital, or phenytoin
- Coadministration with rifampin or rifapentine
- Coadministration with dexamethasone (systemic, more than a single dose)
- Coadministration with St John's wort (Hypericum perforatum)
- Coadministration with proton pump inhibitors (e.g., dexlansoprazole, esomeprazole, lansoprazole, omeprazole, pantoprazole, rabeprazole)
- Known hypersensitivity to enfuvirtide or any excipient of FUZEON
Adverse Reactions
Most common (>=2%) Depressive disorders, headache, insomnia, abnormal dreams, dizziness, nausea, rash
Serious Severe acute exacerbations of hepatitis B, skin and hypersensitivity reactions, hepatotoxicity, depressive disorders, new onset or worsening renal impairment, bone loss and mineralization defects, lactic acidosis/severe hepatomegaly with steatosis, immune reconstitution syndrome
Postmarketing Weight gain, severe skin and hypersensitivity reactions including DRESS, nephrotic syndrome, allergic reaction including angioedema, lactic acidosis, pancreatitis, rhabdomyolysis, osteomalacia, acute renal failure, Fanconi syndrome
Most common Local injection site reactions (pain/discomfort, induration, erythema, nodules/cysts, pruritus, ecchymosis), diarrhea, nausea, fatigue, weight decreased, sinusitis, abdominal pain, cough, herpes simplex, appetite decreased, pancreatitis, pneumonia, myalgia
Serious Pneumonia, hypersensitivity reactions, renal failure, Guillain-Barre syndrome, thrombocytopenia, neutropenia, sepsis, toxic hepatitis, unstable angina pectoris
Postmarketing Cutaneous amyloidosis at the injection site
Pharmacology
COMPLERA is a fixed-dose combination antiretroviral containing emtricitabine (nucleoside reverse transcriptase inhibitor), rilpivirine (non-nucleoside reverse transcriptase inhibitor), and tenofovir disoproxil fumarate (nucleotide reverse transcriptase inhibitor); each component inhibits HIV-1 reverse transcriptase through distinct mechanisms to suppress viral replication.
Enfuvirtide is an HIV-1 fusion inhibitor that binds to the first heptad-repeat (HR1) domain of the gp41 subunit of the viral envelope glycoprotein, preventing the conformational changes required for fusion of viral and cellular membranes and thereby blocking HIV-1 entry into CD4+ cells.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Complera
- Covered on 5 commercial plans
- PA (9/12) · Step Therapy (0/12) · Qty limit (9/12)
Fuzeon
- Covered on 5 commercial plans
- PA (5/12) · Step Therapy (0/12) · Qty limit (1/12)
UnitedHealthcare
Complera
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (8/8)
Fuzeon
- Covered on 4 commercial plans
- PA (4/8) · Step Therapy (2/8) · Qty limit (2/8)
Humana
Complera
- Covered on 0 commercial plans
- PA (0/3) · Step Therapy (0/3) · Qty limit (3/3)
Fuzeon
- Covered on 0 commercial plans
- PA (1/3) · Step Therapy (1/3) · Qty limit (2/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
$0
Gilead Advancing Access Patient Assistance Program/Medication Assistance Program (PAP/MAP)Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
Cost estimate not availableGood Days: HIV, AIDS Treatment & Prevention
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
CompleraView full Complera profile
FuzeonView full Fuzeon profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.